Page 5 - Gamida Cell News Today

WASHINGTON, Aug. 14, 2023 (GLOBE NEWSWIRE) -- As per Vantage Market Research, the Global Stem Cell Therapy Market has been steadily growing due to the increasing importance of medical advancements and technical developments. Both established countries like the United States and developing nations like China and India, where there is an increased emphasis on preventing chronic diseases and preserving overall health cost-efficiently, are particularly in need of effective healthcare solutions. This

Companies Reporting Before The Bell • Safe & Green Holdings (NASDAQ:SGBX) is likely to report quarterly loss at $0.23 per share on revenue of $6.88 million.

Gamida Cell Ltd. reported earnings results for the second quarter and six months ended June 30, 2023. For the second quarter, the company reported net loss was USD 31.68 million compared to USD 18.55... -Today at 07:30 am- MarketScreener

Strong start for Omisirge® launch with significant payer coverage and number of transplant centers onboarded exceeding expectations Company continues to pursue strategic partnership to further... -Today at 07:02 am- MarketScreener

Gamida Cell Ltd. (GMDA), which recently secured FDA approval for its cell therapy Omisirge, on Monday, said that it is seeing high interest from transplant centers, exceeding its expectations.

Gamida Cell Ltd. (NASDAQ:GMDA – Get Free Report) was the target of a large increase in short interest in the month of July. As of July 31st, there was short interest totalling 4,000,000 shares, an increase of 22.7% from the July 15th total of 3,260,000 shares. Based on an average daily volume of 2,260,000 shares, […]

/PRNewswire/ -- The "Allogeneic Cell Therapy: Global Market Report 2023-2035" report has been added to ResearchAndMarkets.coms offering. The global allogeneic...

DUBLIN--(BUSINESS WIRE)--The "Global Allogeneic Cell Therapy Market Trends and Forecasts, 2023-2035" report has been added to ResearchAndMarkets.com's offering.The global allogeneic cell therapy market is projected to witness significant growth in the coming years, with an estimated worth of USD 0.9 billion in 2023,...

Gamida Cell Ltd. (NASDAQ:GMDA – Get Free Report) saw a significant decline in short interest during the month of July. As of July 15th, there was short interest totalling 3,260,000 shares, a decline of 11.4% from the June 30th total of 3,680,000 shares. Based on an average daily volume of 3,080,000 shares, the short-interest ratio […]

Gamida Cell Ltd. (NASDAQ:GMDA – Get Free Report) saw a significant decrease in short interest during the month of June. As of June 30th, there was short interest totalling 3,680,000 shares, a decrease of 13.8% from the June 15th total of 4,270,000 shares. Based on an average daily volume of 5,080,000 shares, the days-to-cover ratio […]